within Pharmacolibrary.Drugs.ATC.L;

model L04AC14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.004833333333333333,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.0073,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Sarilumab is a human monoclonal antibody that binds to the interleukin-6 (IL-6) receptor, inhibiting IL-6 mediated signaling. It is used primarily for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Sarilumab is approved for use in several regions including the United States and Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy subjects and patients with rheumatoid arthritis receiving subcutaneous sarilumab 200 mg. Data chiefly derived from published phase III studies and population PK analyses.</p><h4>References</h4><ol><li><p>Paccaly, AJ, et al., &amp; DiCioccio, AT (2021). Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. <i>Journal of clinical pharmacology</i> 61(1) 90–104. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1703&quot;>10.1002/jcph.1703</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32726514/&quot;>https://pubmed.ncbi.nlm.nih.gov/32726514</a></p></li><li><p>Ishii, T, et al., &amp; Takahashi, T (2023). Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies. <i>Modern rheumatology</i> 33(2) 279–291. DOI:<a href=&quot;https://doi.org/10.1093/mr/roac036&quot;>10.1093/mr/roac036</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35445719/&quot;>https://pubmed.ncbi.nlm.nih.gov/35445719</a></p></li><li><p>Xu, C, et al., &amp; Emery, P (2021). Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters. <i>Journal of clinical pharmacology</i> 61(5) 714–724. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1795&quot;>10.1002/jcph.1795</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33314148/&quot;>https://pubmed.ncbi.nlm.nih.gov/33314148</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC14;
